| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1993-05-19 |
| Identifiers | MRN HR-ML034-SYN; SSN (made up) 000-34-7158 |
| Document date | 2026-05-04 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis visit: biopsy results, the tumor board plan, and the oncology consultation. [S]
Ms. Hansberry returns two weeks after her first visit. Upper endoscopy two days after that visit found no ulcer but an ulcerated mass in the duodenum next to the papilla, oozing slowly, and the biopsies show adenocarcinoma. The pancreas-protocol CT the next day showed a 3.1 cm mass in the head of the pancreas invading the duodenum, with dilated bile and pancreatic ducts and contact with more than half the circumference of the superior mesenteric vein, but no contact with the arteries and no spread to the liver, peritoneum or lungs. Endoscopic ultrasound a week ago confirmed pancreatic adenocarcinoma on biopsy, and a metal stent was placed in the bile duct at the same session; her urine is lighter and the itching has gone. The tumor board reviewed her five days ago. She had two doses of intravenous iron and has had no more black stools. Pain in the upper abdomen and back is 6 out of 10 and wakes her. Her stools are pale and float after fatty meals. She saw Dr. Adeyemi-Rourke this morning and genetic counseling this afternoon. She asked to be told everything plainly and was. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Diagnosis | Adenocarcinoma of the head of the pancreas invading the duodenum; borderline resectable (venous contact more than 180 degrees, no arterial contact); no distant spread |
| Procedures since the first visit | Upper endoscopy with biopsy; pancreas-protocol CT; EUS-guided biopsy; ERCP with a metal biliary stent; two doses of intravenous iron |
| Tumor board | Modified FOLFIRINOX before surgery, restaging, then resection if no progression |
| Symptoms | Pain 6 out of 10; pale floating stools; no more black stools; itching gone |
| Her questions | Whether this can be cured; whether she can keep writing; what the genetic test means for her family; whether she could still have children |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; weight 55.4 kg, down 0.8 kg in two weeks; no fever |
| Gastrointestinal | Positive | Upper abdominal and back pain; pale, floating stools after fatty meals; no black stools since the iron; nausea mild |
| Integumentary | Negative | Itching gone after the stent; no rash |
| Cardiovascular | Negative | No more near-fainting; no leg swelling |
| Genitourinary | Negative | Urine lighter; last period two weeks ago |
| Psychiatric | Positive | Shaken by the diagnosis and determined; PHQ-9 7, GAD-7 8; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 2026-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 2026-04-24 to 2026-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 2026-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 2026-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-04 | Body height | 163 | cm | S |
| 2026-05-04 | Body weight | 55.4 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 92 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.7 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 10.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 7 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-04 | Neutrophils [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 366 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 119 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 141 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-35 U/L | Normal | S |
| 2026-05-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 8-35 U/L | Normal | S |
| 2026-05-04 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 | U/L | 35-104 U/L | High | S |
| 2026-05-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-04 | Albumin [Mass/volume] in Serum or Plasma | 3.5 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-04 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 486 | U/mL | <=35 U/mL | High | S |
| 2026-05-04 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 3.9 | ng/mL | Up to 3.0 ng/mL in non-smokers | High | S |
| 2026-05-04 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-05-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-05-04 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-05-04 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S |
Vital signs recorded on 2026-05-04; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, tired, composed; weight 55.4 kg; blood pressure 108/68, pulse 92 |
| Eyes | Slight scleral icterus, less than at the first visit |
| Abdomen | Tender in the epigastrium without guarding; no mass felt; no liver enlargement; no ascites |
| Lymph nodes | No supraclavicular nodes; no umbilical nodule |
| Extremities | No calf tenderness or leg swelling |
| Psychiatric | Direct, asks exact questions, writes down the answers; tearful briefly |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | active | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis | Before treatment | Up to date | EUS-guided biopsy: adenocarcinoma of the pancreas, moderately differentiated; duodenal biopsies: adenocarcinoma invading from the pancreas |
| Imaging | Pancreas-protocol CT of the abdomen with CT of the chest | At diagnosis, before any treatment | Up to date | Borderline resectable: superior mesenteric vein contact about 200 degrees with reconstructible narrowing; no arterial contact; no metastases |
| Referral | Pancreatic multidisciplinary tumor board | Before treatment for every localized pancreatic cancer | Up to date | Five days ago: modified FOLFIRINOX first, restaging, then resection |
| Laboratory | Biliary drainage and liver tests | Before chemotherapy when the bile duct is blocked | Completed today | Metal stent placed a week ago; bilirubin 0.9 mg/dL (from 1.6), alkaline phosphatase 168 U/L, ALT 30 U/L, AST 28 U/L, albumin 3.5 g/dL |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 486 U/mL, drawn after biliary drainage so that it is not falsely raised by jaundice; CEA 3.9 ng/mL |
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 10.4 g/dL, white cells 7.0, neutrophils 4.6, platelets 366 |
| Laboratory | Kidney function before chemotherapy | Before each cycle | Completed today | Creatinine 0.68 mg/dL, eGFR 119 |
| Laboratory | INR before port placement | Before the procedure | Completed today | 1.0 |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today |
| Laboratory | Pregnancy test | Before chemotherapy | Completed today | Urine pregnancy test negative |
| Referral | Genetic counseling | At diagnosis of pancreatic cancer | Completed today | Pedigree taken; no known pancreatic, breast, ovarian, prostate or colorectal cancer in her family; consent given |
| Laboratory | Germline multigene panel | Once, at diagnosis, for every patient with pancreatic cancer | Ordered | Includes BRCA1, BRCA2, PALB2, ATM, CDKN2A, the Lynch syndrome genes, STK11 and TP53; result in about three weeks |
| Laboratory | Tumor molecular profiling | At diagnosis, on tissue | Ordered | Next-generation sequencing on the EUS cores, with mismatch repair status and fusion testing |
| Referral | Fertility counseling | Before gonadotoxic chemotherapy | Completed today | Oxaliplatin and irinotecan may reduce fertility. Egg or embryo freezing would delay chemotherapy by about two weeks; she chose not to delay treatment, which was respected. Effective non-estrogen contraception advised |
| Referral | Palliative care | From diagnosis, alongside cancer treatment | Referred | Outpatient palliative care consultation in two days |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 6 out of 10; oxycodone 5 mg as needed started with senna |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 55.4 kg; pancrelipase started; dietitian referral this week |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Fasting glucose 141 mg/dL: with the A1c of 6.6%, diabetes is confirmed |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Due | To be arranged now that diabetes is confirmed |
| Medication safety | Venous thromboembolism risk (Khorana score) | At the start of chemotherapy | Completed today | Khorana score 3 (pancreatic primary, hemoglobin under 10 g/dL at the first visit). Primary prophylaxis with apixaban is recommended for this score, but it is held for now because the duodenal tumor bled within the last month; to start when there has been no bleeding for several weeks |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 7 and GAD-7 8, mild, with fear about the diagnosis; no thoughts of self-harm |
| Self-management | Plain information and support she chooses | At diagnosis and throughout | Completed today | Plain explanation of the diagnosis, its stage and the aim of treatment, with written information; she chose who would be told and who receives her notes |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine (PCV20), before chemotherapy; Recombinant zoster vaccine, dose 1 of 2, before chemotherapy [S]
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38(31):3698-3715 (PMID 32716741) (2020); Oktay K, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36(19):1994-2001 (PMID 29620997) (2018); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); Noel M, Fiscella K. Disparities in Pancreatic Cancer Treatment and Outcomes. Health Equity 2019;3(1):532-540 (PMID 31663065) (2019); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Palliative care in two days; port next week; cycle 1 in two weeks. Primary care review at cycle 4. Call at once for fever, yellow eyes, black stools, fainting, or leg swelling. Next scheduled visit 2026-06-29: day 1 of cycle 4 of modified FOLFIRINOX: toxicity review, genetic and tumor profiling results, thromboprophylaxis, nutrition and mood. [S]